Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice
Omalizumab significantly improved symptoms and QOL in patients with JCP. However, its high cost and the risk of nonresponse necessitate careful patient selection. Age and IgE levels may help guide treatment decisions, highlighting the importance of individualized strategies for severe JCP.
Authors
- Toshio Miki (ORCID: https://orcid.org/0000-0001-5546-6770)
- Hiroshi Utsunomiya
- Momoko Takeda
Institutions
- Kanazawa University (JP)
- Nihon University (JP)
- KDDI Research (Japan) (JP)
Publication Details
- Journal
- Allergy Asthma and Clinical Immunology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s13223-025-00995-y
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- article
- Field-Weighted Citation Impact
- 0.00